Profounda receives FDA Orphan Drug Designation for miltefosine for treating Primary Amebic Meningoencephalitis (PAM)
Profounda, Inc. announced Friday that it has received, the US Food and Drug Administration’s (FDA) Orphan Drug Designation for the treatment of Primary Amebic Meningoencephalitis (PAM) with miltefosine. More...
Arkansas girl, Kali Hardig making great progress in her recovery, What is this experimental anti-amoeba drug?
Aug. 7 Update: It was posted on Prayers For Kali Le Ann last night–“They took Kali off the vent! She is moving and responding to questions! We are fly high on every breath she takes! Keep the prayers More...
